S M Langan1, H C Williams. 1. Centre of Evidence-based Dermatology, University of Nottingham, Nottingham, UK. sinead.langan@nottingham.ac.uk
Abstract
BACKGROUND: Many interventions have been described for inherited epidermolysis bullosa (EB), but it is unclear which are beneficial. AIMS: A systematic review of randomized controlled trials (RCTs) was performed to inform practice and highlight research gaps. METHODS: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and the Cochrane Skin Group specialist library, from inception until 1 April 2007, were searched. Primary outcomes were healing of lesions or prevention of new lesions. Trials were assessed for quality of reporting and data were extracted. RESULTS: Five randomized double-blind placebo-controlled crossover studies were identified (n = 102). Two studies assessed oral tetracyclines in EB simplex (EBS). In one study (n = 12), 4/6 patients improved and 2/6 deteriorated on a dose of 1500 mg of tetracycline daily; only two patients completed the study. In the second study (n = 21), 6/18 and 7/18 improved on oxytetracycline 1 g and placebo, respectively. Two RCTs assessed topical interventions for EBS: aluminium chloride hexahydrate solution 20% (n = 23) and bufexamac cream 5% (n = 8). Neither showed a benefit over placebo. One RCT of 36 patients with recessive dystrophic EB compared phenytoin with placebo and failed to show any difference in mean lesion counts (difference = 0, 95% CI -11 to 4). CONCLUSIONS: There is no reliable trial evidence for interventions in inherited EB. In future, it may be that gene treatment becomes the best treatment approach for these diseases.
BACKGROUND: Many interventions have been described for inherited epidermolysis bullosa (EB), but it is unclear which are beneficial. AIMS: A systematic review of randomized controlled trials (RCTs) was performed to inform practice and highlight research gaps. METHODS: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and the Cochrane Skin Group specialist library, from inception until 1 April 2007, were searched. Primary outcomes were healing of lesions or prevention of new lesions. Trials were assessed for quality of reporting and data were extracted. RESULTS: Five randomized double-blind placebo-controlled crossover studies were identified (n = 102). Two studies assessed oral tetracyclines in EB simplex (EBS). In one study (n = 12), 4/6 patients improved and 2/6 deteriorated on a dose of 1500 mg of tetracycline daily; only two patients completed the study. In the second study (n = 21), 6/18 and 7/18 improved on oxytetracycline 1 g and placebo, respectively. Two RCTs assessed topical interventions for EBS: aluminium chloride hexahydrate solution 20% (n = 23) and bufexamac cream 5% (n = 8). Neither showed a benefit over placebo. One RCT of 36 patients with recessive dystrophic EB compared phenytoin with placebo and failed to show any difference in mean lesion counts (difference = 0, 95% CI -11 to 4). CONCLUSIONS: There is no reliable trial evidence for interventions in inherited EB. In future, it may be that gene treatment becomes the best treatment approach for these diseases.
Authors: Jean Christopher Chamcheu; Gary S Wood; Imtiaz A Siddiqui; Deeba N Syed; Vaqar M Adhami; Joyce M Teng; Hasan Mukhtar Journal: Exp Dermatol Date: 2012-07 Impact factor: 3.960
Authors: Márcia Carolline dos Santos Sousa; Carmen Dea Ribeiro de Paula; Pedro Luiz Tauil; Izelda Maria Carvalho Costa Journal: An Bras Dermatol Date: 2015 Nov-Dec Impact factor: 1.896
Authors: Amy S Paller; John Browning; Milos Nikolic; Christine Bodemer; Dedee F Murrell; Willistine Lenon; Eva Krusinska; Allen Reha; Hjalmar Lagast; Jay A Barth Journal: Orphanet J Rare Dis Date: 2020-06-23 Impact factor: 4.123
Authors: Vanessa Lys Simas Yamakawa Boeira; Erica Sales Souza; Bruno de Oliveira Rocha; Pedro Dantas Oliveira; Maria de Fátima Santos Paim de Oliveira; Vitória Regina Pedreira de Almeida Rêgo; Ivonise Follador Journal: An Bras Dermatol Date: 2013 Mar-Apr Impact factor: 1.896